特发性肺纤维化诊断与预后生物标志物研究进展  

Research progress on biomarkers in the diagnosis and treatment of idiopathic pulmonary fibrosis

作　　者：胡莉娟 刘若雨 周允[2] 曹永彤[2] Hu Lijuan;Liu Ruoyu;Zhou Yun;Cao Yongtong(Graduate School of China-Japan Friendship Hospital,Beijing 100730,China;Clinical Laboratory,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]北京协和医学院研究生院,北京100730 [2]中日友好医院检验科,北京100029

出　　处：《中华检验医学杂志》2024年第10期1123-1125,共3页Chinese Journal of Laboratory Medicine

摘　　要：特发性肺纤维化(IPF)是临床诊断较为困难的间质性肺病,寻找合适的生物标志物辅助IPF的诊断和预后监测,可以提高IPF患者早期诊断、及时治疗的比例,提高患者生存质量。Idiopathic pulmonary fibrosis(IPF)is an interstitial lung disease that is difficult to diagnose clinically,and finding appropriate biomarkers to assist in the diagnosis and prognosis monitoring of IPF can improve the proportion of early diagnosis and timely treatment of these patients and improve the quality of life of patients.

关 键 词：肺纤维化 间质性肺病 生物标志物 临床应用 

分 类 号：R563[医药卫生—呼吸系统]